NovaBay® Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
Corporate Presentation on July 30 in Boca Raton, Florida

EMERYVILLE, Calif. — July 24, 2009 — NovaBay® Pharmaceuticals, Inc. (NYSE-AMEX: NBY, http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Jesup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 9:30 am EDT. The presentation will be held at The Boca Raton Resort & Club in Boca Raton, Florida.

Dr. Najafi will provide a corporate overview and highlight NovaBay’s clinical progress, business development strategy and product development candidates. His presentation will:

  • Update investors on NovaBay’s internal clinical programs in hospital-associated infections and respiratory infections.
  • Provide information on NovaBay’s recent announcements regarding the initiation of a Phase II clinical trial for the use of NovaBay’s lead Aganocide® compound, NVC-422, for viral conjunctivitis, which is being conducted by its partner Alcon (NYSE:ACL).
  • Review the recently announced partnership with Galderma, the world’s leading dermatology company, for development of acne and impetigo products
  • Discuss the important collaborative agreement with professors Markus Nagl, M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria, which broadens NovaBay’s intellectual property estate, expands its pre-clinical pipeline and advances the development of NovaBay’s Aganocide® compounds by integrating on-going clinical work at the Medical University with NovaBay’s development programs.

In addition, Dr. Najafi will serve on a key conference panel that will include industry leaders and a former FDA Commissioner to discuss trends in the biotech industry and biotech investing. The panel session will take place at 4:45 pm EDT on Wednesday, July 29, 2009.

About Aganocide® Compounds

The Aganocide® compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay® to mimic the body’s natural defense against infection. The Aganocide® compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated, first-in-class, small molecule, patented new chemical entities may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide® compounds have been shown to be highly effective against bacteria, including its multi-drug resistant strains, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency and tolerability as well as dosing versatility and flexibility.

About NovaBay

NovaBay® Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide® compounds, which are novel, synthetic, anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay® has internal development programs aimed at addressing dermatological, hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide® compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay® has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.

Contact:
NovaBay® Pharmaceuticals, Inc.
Thomas J. Paulson
Chief Financial Officer
510-899-8809
tpaulson@novabaypharma.com

Novabay